Mirati Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of oncology products including candidates intended to treat specific genetic and epigenetic drivers of cancer in selected subsets of cancer patients with unmet needs. The Company's clinical pipeline consists of three product candidates: glesatinib, sitravatinib and mocetinostat. Both glesatinib and sitravatinib are orally-bioavailable, spectrum-selective kinase inhibitors with distinct target profiles that are in development for the treatment of patients with NSCLC and other solid tumors.
Type | Public | |
Founded | 2013 | |
HQ | San Diego, CA, US | Map |
Website | mirati.com |
USD | |
---|---|
Revenue (Q3, 2020) | 11.4m |
Net income (Q3, 2020) | (87.3m) |
EBIT (Q3, 2020) | (88.7m) |
Market capitalization (23-Feb-2021) | 10.1b |
Closing stock price (23-Feb-2021) | 200.9 |
Cash (30-Sept-2020) | 131.4m |
USD | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue | 9.5m | 1.2m | 577.0k | 988.0k | 267.0k | 11.4m | |||||||||||||||||
General and administrative expense | 2.4m | 3.7m | 2.4m | 2.9m | 3.5m | 3.8m | 4.2m | 4.2m | 4.1m | 3.8m | 3.5m | 3.7m | 3.7m | 3.1m | 5.2m | 4.8m | 5.3m | 9.8m | 9.9m | 10.7m | 18.0m | 19.8m | 20.2m |
R&D expense | 4.5m | 5.5m | 5.2m | 7.2m | 7.0m | 8.2m | 11.3m | 14.6m | 18.0m | 18.4m | 16.1m | 14.4m | 15.0m | 13.5m | 19.7m | 23.8m | 23.6m | 34.2m | 38.3m | 47.4m | 71.7m | 65.1m | 79.9m |
Operating expense total | 6.9m | 9.2m | 8.0m | 10.1m | 10.5m | 12.0m | 15.5m | 18.7m | 22.1m | 22.2m | 19.6m | 18.1m | 18.6m | 16.6m | 24.8m | 28.7m | 28.9m | 44.0m | 48.2m | 58.0m | 89.8m | 84.9m | 100.1m |
USD | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Cash | 9.7m | 7.6m | 8.3m | 8.5m | 4.9m | 14.3m | 13.4m | 109.9m | 34.6m | 24.5m | 19.8m | 29.8m | 20.0m | 20.8m | 20.6m | 106.0m | 116.7m | 74.6m | 252.1m | 91.9m | 204.5m | 131.7m | 131.4m |
Accounts Receivable | 66.0k | ||||||||||||||||||||||
Prepaid Expenses | 1.8m | 1.5m | 2.7m | 1.7m | 2.6m | 3.2m | 2.0m | 3.0m | 2.2m | 1.7m | 2.5m | 2.5m | 4.4m | 4.4m | 4.4m | 3.4m | 3.5m | 5.4m | 10.2m | 10.4m | 9.5m | 8.3m | 16.3m |
Current Assets | 22.4m | 17.0m | 56.0m | 49.2m | 40.3m | 71.2m | 60.9m | 141.0m | 109.9m | 93.0m | 75.5m | 107.9m | 92.3m | 79.4m | 153.1m | 263.6m | 246.1m | 306.4m | 495.7m | 464.6m | 704.8m | 654.0m | 595.4m |
USD | FY, 2013 | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|---|
Net Income | (52.9m) | (43.7m) | (64.5m) | (83.1m) | (70.4m) | (98.4m) | (213.3m) |
Depreciation and Amortization | 171.0k | 199.0k | 212.0k | 180.0k | 184.0k | 175.0k | 249.0k |
Accounts Payable | (68.0k) | 151.0k | 4.4m | 5.2m | (1.3m) | 12.9m | 23.0m |
Cash From Operating Activities | (29.5m) | (32.7m) | (50.7m) | (68.0m) | (64.7m) | (70.1m) | (147.7m) |
USD | Q2, 2013 | Q3, 2013 | Q1, 2014 | Q2, 2014 | Q3, 2014 | Q1, 2015 | Q2, 2015 | Q3, 2015 | Q1, 2016 | Q2, 2016 | Q3, 2016 | Q1, 2017 | Q2, 2017 | Q3, 2017 | Q1, 2018 | Q2, 2018 | Q3, 2018 | Q1, 2019 | Q2, 2019 | Q3, 2019 | Q1, 2020 | Q2, 2020 | Q3, 2020 |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Income | (12.2m) | (41.6m) | (13.7m) | (24.7m) | (33.3m) | (11.9m) | (27.4m) | (46.1m) | (21.9m) | (44.0m) | (63.4m) | (17.8m) | (36.2m) | (52.5m) | (14.7m) | (42.6m) | (70.1m) | (40.9m) | (86.6m) | (140.9m) | (86.7m) | (169.5m) | (256.8m) |
Depreciation and Amortization | 64.0k | 105.0k | 78.0k | 116.0k | 154.0k | 44.0k | 100.0k | 153.0k | 58.0k | 100.0k | 45.0k | 41.0k | 131.0k | 44.0k | 99.0k | 126.0k | 253.0k | ||||||
Accounts Payable | (756.0k) | 1.3m | (1.3m) | 649.0k | 111.0k | (482.0k) | 1.7m | 4.4m | 1.0m | 4.0m | 3.8m | (3.5m) | (3.1m) | (3.3m) | 2.7m | 4.9m | 8.6m | (1.1m) | 2.1m | 9.3m | 6.9m | 8.8m | 17.3m |
Cash From Operating Activities | (16.5m) | (21.7m) | (8.8m) | (14.5m) | (24.2m) | (9.8m) | (18.8m) | (34.7m) | (17.0m) | (33.6m) | (51.9m) | (18.2m) | (35.8m) | (50.9m) | (7.9m) | (29.1m) | (49.3m) | (34.5m) | (72.9m) | (105.8m) | (59.0m) | (118.3m) | (195.1m) |
USD | Q2, 2013 |
---|---|
Financial Leverage | 3.7 x |
FY, 2016 | |
---|---|
Patents Issued | 32 |
Patents Pending | 1 |
Mirati Therapeutics has 346 Twitter Followers. The number of followers has increased 6.3% month over month and increased 15.1% quarter over quarter
When was Mirati Therapeutics founded?
Mirati Therapeutics was founded in 2013.
Who are Mirati Therapeutics key executives?
Mirati Therapeutics's key executives are Charles M. Baum, Julie M. Cherrington and James Christensen.
How many employees does Mirati Therapeutics have?
Mirati Therapeutics has 111 employees.
What is Mirati Therapeutics revenue?
Latest Mirati Therapeutics annual revenue is $3.3 m.
What is Mirati Therapeutics revenue per employee?
Latest Mirati Therapeutics revenue per employee is $30 k.
Who are Mirati Therapeutics competitors?
Competitors of Mirati Therapeutics include OncoStem Diagnostics, Acerta Pharma and Vaxon Biotech.
Where is Mirati Therapeutics headquarters?
Mirati Therapeutics headquarters is located at 9393 Towne Centre Dr #200, San Diego.
Where are Mirati Therapeutics offices?
Mirati Therapeutics has an office in San Diego.
How many offices does Mirati Therapeutics have?
Mirati Therapeutics has 1 office.
Receive alerts for 300+ data fields across thousands of companies